

EFFECTIVENESS AND SAFETY OF ERENUMAB IN MIGRAINE PROPHYLAXIS

¹C. MONTERO-VILCHEZ¹, A. MARTIN-ROLDAN¹, S. CANO-DOMINGUEZ¹, A.Y. SALMERON-COBOS¹, A. ESPINOSA-RODRIGUEZ¹, M.R. CANTUDO CUENCA¹ ✉ carolinamonvil95@gmail.com

VIRGEN DE LAS NIEVES UNIVERSITY HOSPITAL, PHARMACY DEPARTMENT, GRANADA, SPAIN.

BACKGROUND AND IMPORTANCE

- Migraine is **the second most prevalent** disease in terms of disability-adjusted life years (DALYs).
- Erenumab**, a novel calcitonin gene-related peptide receptor antagonist, has been developed for **migraine prevention**.

AIM AND OBJETIVES

To evaluate **effectiveness and safety** of erenumab in migraine prophylaxis.


MATERIAL AND METHODS

- Retrospective, observational study.**
- Period:** September-2019 to September-2021.

Variables collected	
Demographic (sex, age)	Presence of aura
Type of migraine	Dose
Headache Impact Test-6 (HIT-6)	Baselina Migraine Dissability Assessment Scale (MIDAS)
Number of previous treatments	Migraine days measured in the last three months
Duration of treatment	

- Effectiveness:** Evaluated by a **monthly reduction of ≥50% in migraine days** measured at week 12 from start date.
- Safety:** Evaluated measuring **adverse reactions**.
- Information sources:** electronic prescription programme ATHOS-Prisma® and computerized medical record Diraya®

RESULTS



CONCLUSION AND RELEVANCE

- Erenumab is an **effective and safe** alternative in the prophylaxis of migraine refractory to other therapies.
- More and longer studies are needed to establish the utility of this drug in clinical practice and their long-term safety.